Publications

Metachromatic leukodystrophy (MLD) (9 POSTS)

2024 (3 POSTS)

Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative

Olaye A, Bean K, Velikanova R, Wolters S, Miller B, Jensen I, Pang F. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative. Abstract EE693, ISPOR Europe 2024, November 2024.

View Abstract

The 18-effectiveness of atidarsagene autotemcel (ARSA-CEL) for the treatment of metachromatic leukodystrophy (MLD) in Spain

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. The 18-effectiveness of atidarsagene autotemcel (ARSA-CEL) for the treatment of metachromatic leukodystrophy (MLD) in Spain, ISPOR Europe 2024, November 2024.

Exploring the cost-effectiveness of newborn screening for metachromatic leukodystrophy (MLD) in the UK

Bean K, Jones SA, Chakrapani A, Vijay S, Wu T, Church H, … Jensen I, et al. 2024. Exploring the cost-effectiveness of newborn screening for metachromatic leukodystrophy (MLD) in the UK. Int J Neonatal Screen 10(3):45; doi: 10.3390/ijns10030045.

View Abstract

2023 (4 POSTS)

The societal costs of metachromatic leukodystrophy (MLD) in the United States

Bean K, Miller B, Jensen I, Howle K, Wilds A, Walz M, et al. The societal costs of metachromatic leukodystrophy (MLD) in the United States. Abstract EE547, ISPOR EU 2023.

View Abstract

Evaluating the face validity of health state utility values (HSUVS) for metachromatic leukodystrophy (MLD)

Bean K, Miller B, Jensen I, Fields C, Pang F. Evaluating the face validity of health state utility values (HSUVS) for metachromatic leukodystrophy (MLD). Abstract EE285, ISPOR 2023.

View Abstract

Direct cost analysis associated with the management of patients with metachromatic leukodystrophy (MLD) across nine European countries

Bean K, Olaye A, Miller B, Jensen I, Dean R, Pang F. Direct cost analysis associated with the management of patients with metachromatic leukodystrophy (MLD) across nine European countries. Abstract EE408, ISPOR 2023.

View Abstract

The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. 2023. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Mol Gene Metab 138(2):107258; doi: 10.1016/j.ymgme.2022.107258.

2022 (1 POST)

The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy (MLD) in France

Pang F, Dean R, Jensen I, Tehard B, Roze S, Olaye A, et al. The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy (MLD) in France. Abstract EE24, ISPOR 2022.

View Abstract

2021 (1 POST)

The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the U

Pang F, Dean R, Jensen I, Olaye A, Miller B. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Abstract PRO30, ISPOR 2021.

View Abstract